Helixmith Co., Ltd (084990.KQ)
KRW 2770.0
(0.0%)
KRW 2770.0
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.2 Billion KRW | 50.08% |
| 2022 | 2.79 Billion KRW | 20.87% |
| 2021 | 2.31 Billion KRW | -45.48% |
| 2020 | 4.24 Billion KRW | -4.63% |
| 2019 | 4.45 Billion KRW | 42.45% |
| 2018 | 3.12 Billion KRW | -0.98% |
| 2017 | 3.15 Billion KRW | -53.86% |
| 2016 | 6.84 Billion KRW | -11.06% |
| 2015 | 7.69 Billion KRW | 0.0% |
| 2013 | 5.74 Billion KRW | 47.78% |
| 2012 | 3.88 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 817.6 Million KRW | 51.78% |
| 2024 Q2 | 720.46 Million KRW | -11.88% |
| 2023 Q4 | 538.66 Million KRW | -50.68% |
| 2023 FY | 4.2 Billion KRW | 50.08% |
| 2023 Q1 | 1.47 Billion KRW | 95.7% |
| 2023 Q2 | 1.09 Billion KRW | -25.24% |
| 2023 Q3 | 1.09 Billion KRW | -0.69% |
| 2022 FY | 2.79 Billion KRW | 20.87% |
| 2022 Q2 | 504.6 Million KRW | -64.51% |
| 2022 Q3 | 769.97 Million KRW | 52.59% |
| 2022 Q1 | 1.42 Billion KRW | 68.36% |
| 2022 Q4 | 751.67 Million KRW | -2.38% |
| 2021 Q3 | 651.75 Million KRW | 51.13% |
| 2021 Q4 | 844.55 Million KRW | 29.58% |
| 2021 FY | 2.31 Billion KRW | -45.48% |
| 2021 Q2 | 431.26 Million KRW | 10.96% |
| 2021 Q1 | 388.67 Million KRW | -59.46% |
| 2020 FY | 4.24 Billion KRW | -4.63% |
| 2020 Q1 | 838.08 Million KRW | -50.05% |
| 2020 Q2 | 1.49 Billion KRW | 78.21% |
| 2020 Q3 | 957.87 Million KRW | -35.87% |
| 2020 Q4 | 958.75 Million KRW | 0.09% |
| 2019 Q2 | 954.03 Million KRW | 104.98% |
| 2019 FY | 4.45 Billion KRW | 42.45% |
| 2019 Q1 | 465.41 Million KRW | -46.89% |
| 2019 Q4 | 1.67 Billion KRW | 23.61% |
| 2019 Q3 | 1.35 Billion KRW | 42.27% |
| 2018 FY | 3.12 Billion KRW | -0.98% |
| 2018 Q3 | 718.79 Million KRW | -32.08% |
| 2018 Q4 | 876.36 Million KRW | 21.92% |
| 2018 Q2 | 1.05 Billion KRW | 123.46% |
| 2018 Q1 | 473.62 Million KRW | -47.59% |
| 2017 Q3 | 832.3 Million KRW | -18.8% |
| 2017 FY | 3.15 Billion KRW | -53.86% |
| 2017 Q2 | 1.02 Billion KRW | 158.16% |
| 2017 Q1 | 397.02 Million KRW | 0.0% |
| 2017 Q4 | 903.61 Million KRW | 8.57% |
| 2016 FY | 6.84 Billion KRW | -11.06% |
| 2015 FY | 7.69 Billion KRW | 0.0% |
| 2014 Q1 | 525.05 Million KRW | -77.71% |
| 2014 Q3 | 972.63 Million KRW | -28.06% |
| 2014 Q2 | 1.35 Billion KRW | 157.5% |
| 2013 FY | 5.74 Billion KRW | 47.78% |
| 2013 Q3 | 1.25 Billion KRW | -0.83% |
| 2013 Q2 | 1.26 Billion KRW | 43.85% |
| 2013 Q1 | 877.15 Million KRW | 55.03% |
| 2013 Q4 | 2.35 Billion KRW | 88.22% |
| 2012 FY | 3.88 Billion KRW | 0.0% |
| 2012 Q4 | 565.8 Million KRW | -68.14% |
| 2012 Q3 | 1.77 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Co., Ltd. | 42.9 Billion KRW | 90.206% |
| iNtRON Biotechnology, Inc. | 9.58 Billion KRW | 56.167% |
| BINEX Co., Ltd. | 154.82 Billion KRW | 97.286% |
| Bioneer Corporation | 263.23 Billion KRW | 98.404% |
| Anterogen.Co.,Ltd. | 6.5 Billion KRW | 35.362% |
| MEDIPOST Co., Ltd. | 68.64 Billion KRW | 93.879% |
| CrystalGenomics, Inc. | 4.87 Billion KRW | 13.878% |
| Chabiotech Co.,Ltd. | 953.95 Billion KRW | 99.56% |
| Medy-Tox Inc. | 221.12 Billion KRW | 98.1% |
| Peptron, Inc. | 3.34 Billion KRW | -25.726% |
| Amicogen, Inc. | 159.9 Billion KRW | 97.372% |
| Genexine, Inc. | 4.42 Billion KRW | 5.083% |
| HLB Therapeutics Co.,Ltd. | 53.74 Billion KRW | 92.183% |
| LegoChem Biosciences, Inc. | 34.14 Billion KRW | 87.695% |
| ALTEOGEN Inc. | 96.52 Billion KRW | 95.647% |
| PharmaResearch Co., Ltd. | 261.01 Billion KRW | 98.39% |
| SillaJen, Inc. | 3.93 Billion KRW | -6.652% |
| JETEMA, Co., Ltd. | 58.71 Billion KRW | 92.844% |
| OliX Pharmaceuticals,Inc | 17.06 Billion KRW | 75.378% |
| Genomictree Inc. | 3.41 Billion KRW | -22.926% |
| MedPacto, Inc. | - KRW | -Infinity% |
| D&D Pharmatech | 18.67 Billion KRW | 77.504% |
| EASY BIO,Inc. | 165.38 Billion KRW | 97.459% |
| GI Innovation, Inc. | 5.31 Billion KRW | 21.005% |